ERBB2 and neoplasm: Some studies have shown that HER2 overexpression/amplification, as an adverse prognostic factor, is closely correlated with the tumor stage and survival in CRC patients (Ingold Heppner et al. 2014; Kapitanovic et al. 1997; Osako et al. 1998).